Healio Rheumatology Current Issue

The following articles appeared in the print edition of Healio Rheumatology.

Table of Contents

• Mindset Matters: Harnessing the Placebo Effect for Patient Benefit Rob Volansky
• FDA Approves Secukinumab Label Update for Dosing Flexibility in AS
• FDA Grants Orphan Drug Status to IV Immunoglobulin Treatment for Systemic Sclerosis
• Embracing the Placebo Effect: The Time has Arrived for Rheumatology Leonard H. Calabrese, DO
• Diagnosis Detective: Discerning Vasculitis From its Many Mimics Rob Volansky
• Updated EULAR Recommendations for RA Allow Larger Role for JAK Inhibitors Jason Laday
• Giant Cell Arteritis Curbside Consults: Patient Presenting to the Emergency Department With New-Onset Visual Symptoms
• Trump’s Claim to have ‘Saved’ Pre-existing Conditions Clashes With Record Jason Laday
• Abatacept Linked to Major Clinical RA Response in Men, Biologic-naive Jason Laday
• Less Than 40% of Patients With High RA Disease Activity Modify Treatment Jason Laday
• Neuropsychiatric Events Most Frequent Near SLE Diagnosis, Linked to Excess Mortality Jason Laday
• Optimal RA Management Reduces Risk for Adverse Pregnancy Outcomes Jason Laday
• Patients, Caregivers Weigh Disease, Treatment Risks When Deciding to End JIA Therapy Jason Laday
• Patients With Moderate PsA Disease More Likely to Meet Treatment Targets With Apremilast Jason Laday
• Patients With RA Skeptical of Patient-reported Outcome Measures Jason Laday
• Physicians Should Counsel Patients on Safe Use of Cannabis Edibles Jason Laday
• Symptomatic, Radiographic Knee OA Linked to Increased Mortality Risk Jason Laday
• Tofacitinib Linked to Twofold Greater Risk for Herpes Zoster in RA Jason Laday
• Two-thirds of Patients With PsA Waited 6 Months or More for Diagnosis Jason Laday
• As Shortage Looms, Tele-rheumatology Offers Solutions, Novel Legal Risks Robert Stott
• Daytime-only NSAID Dosing May Foster Improved Healing, Recovery Robert Stott
• Failure to ‘Move the Needle’ in OA Driving Joint Replacement Boom Robert Stott
• Head-to-head Trials Open New Data in PsA With ‘Cautionary’ Interpretation Rob Volansky
• Alternative Therapies Offer Mild Benefit, ‘Lousy Data’ for OA Robert Stott
• APS Foundation of America Takes Aim at the Antiphospholipid Knowledge Gap Rob Volansky
• ACR, Seven Medical Societies Warn BlueCross BlueShield Against New In-office Treatment Policy Jason Laday
• Cost Savings From Infliximab Biosimilars ‘Insufficient’ to Promote Use in US Jason Laday
• FDA Approves Voltaren Arthritis Pain for Nonprescription, OTC Use Jason Laday
• FDA, Federal Trade Commission to Target ‘Anti-competitive’ Practices to Support Biosimilars Jason Laday